Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 9/20 | 0.56 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | THRB | P10828 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.49 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.45 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.45 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.43 |
| ▸ | KMO | O15229 | 2/20 | 0.42 |
| ▸ | FYN | P06241 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12326172 | 0.86 | PTGS2 (0.53) | PTGS2PTGS1MEN1ALDH1A1KMT2A | |
| SCHEMBL8656197 | 0.84 | CYP17A1 (0.56) | PTGS2PTGS1MAPTMEN1ALDH1A1 | |
| SCHEMBL13906296 | 0.83 | PTGS2 (0.50) | PTGS2PTGS1KMT2APDGFRBPDGFRA | |
| SCHEMBL14270106 | 0.82 | TUBB1 (0.49) | PTGS2PTGS1MAPTMEN1ALDH1A1 | |
| SCHEMBL13906291 | 0.79 | CYP17A1 (0.55) | PTGS2PTGS1MAPTMEN1ALDH1A1 | |
| SCHEMBL4454422 | 0.79 | AHR (0.56) | PTGS2PTGS1MEN1ALDH1A1KMT2A | |
| SCHEMBL19270949 | 0.78 | FYN (0.49) | PTGS2PTGS1ALDH1A1PDGFRBPDGFRA | |
| SCHEMBL17694924 | 0.78 | ERN1 (0.55) | PTGS2PTGS1MAPTKMT2APDGFRB | |
| SCHEMBL9464193 | 0.78 | CYP17A1 (0.61) | PTGS2PTGS1MAPTMEN1ALDH1A1 | |
| SCHEMBL19270951 | 0.77 | MGLL (0.52) | PTGS2PTGS1PDGFRBPDGFRAHSD17B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050113376-A1 | Compositions of a cyclooxygenase-2 selective inhibitor, a xanthine compound and an alcohol for the treatment of ischemic mediated central nervous system disorders or injury | PHARMACIA CORPORATION | 2005-05-26 | — | — | US | disclosed |
| US-20050085477-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a serotonin-modulating agent for the treatment of neoplasia | PHARMACIA CORPORATION | 2005-04-21 | — | — | US | disclosed |
| US-20050009733-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a potassium ion channel modulator for the treatment of central nervous system damage | PHARMACIA CORPORATION | 2005-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050085477-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a serotonin-modulating agent for the treatment of neoplasia | TPH2, TPH1, HTR2A | PTGS2 15/4885PTGS1 23/4885MAPT 3499/4885 |
| US-20050009733-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a potassium ion channel modulator for the treatment of central nervous system damage | KCNJ2, KCNN2, KCNK2 | PTGS2 4/4885PTGS1 30/4885MAPT 2497/4885 |
| US-20050113376-A1 | Compositions of a cyclooxygenase-2 selective inhibitor, a xanthine compound and an alcohol for the treatment of ischemic mediated central nervous system disorders or injury | XDH, PTGS2, PTGS1 | PTGS2 2/4885PTGS1 3/4885MAPT 1697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.